Matches in Wikidata for { <http://www.wikidata.org/entity/Q83806227> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q83806227 description "clinical trial" @default.
- Q83806227 description "ensayu clínicu" @default.
- Q83806227 description "klinisch onderzoek" @default.
- Q83806227 description "клінічне випробування" @default.
- Q83806227 description "կլինիկական փորձարկում" @default.
- Q83806227 name "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 name "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 type Item @default.
- Q83806227 label "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 label "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 prefLabel "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 prefLabel "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 P1050 Q83806227-975FBB32-D129-467F-8EF4-6D244E997FDF @default.
- Q83806227 P1050 Q83806227-D2788A50-405A-4E83-A062-DF3ABCE44EF5 @default.
- Q83806227 P1132 Q83806227-25E7EC67-F8C8-4B16-B68B-AC5015A5B8B3 @default.
- Q83806227 P1476 Q83806227-C1E23092-73F8-4179-9B93-6506D013A1CA @default.
- Q83806227 P17 Q83806227-B1C5584D-F756-43C7-ACFD-98277C5C6582 @default.
- Q83806227 P1813 Q83806227-D5E8FBEF-6528-4A49-BAE4-6BAE9153DD54 @default.
- Q83806227 P2899 Q83806227-98D20830-16DD-403D-8DB9-F0C3750B203D @default.
- Q83806227 P3098 Q83806227-7FEDC5D5-045B-4707-807E-DBFCDB9BF777 @default.
- Q83806227 P31 Q83806227-EA443813-86B4-4701-9ECC-4DF9EAF5DBCC @default.
- Q83806227 P4135 Q83806227-E287A8C2-58DD-4B86-B55F-20F1AE1DB1F2 @default.
- Q83806227 P580 Q83806227-08589C51-4B78-486E-B95B-6266207EDFF7 @default.
- Q83806227 P582 Q83806227-7DDF5E2E-B322-418F-8167-A596BF2DA884 @default.
- Q83806227 P6099 Q83806227-9AA15BD5-A131-44AA-B6FB-D7DBE48E4C81 @default.
- Q83806227 P8363 Q83806227-7B010443-0CF2-45F0-8853-6EDA92DDB664 @default.
- Q83806227 P1050 Q101991 @default.
- Q83806227 P1050 Q12206 @default.
- Q83806227 P1132 "+24" @default.
- Q83806227 P1476 "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes" @default.
- Q83806227 P17 Q39 @default.
- Q83806227 P1813 "Cephalira" @default.
- Q83806227 P2899 "+18" @default.
- Q83806227 P3098 "NCT04227769" @default.
- Q83806227 P31 Q30612 @default.
- Q83806227 P4135 "+70" @default.
- Q83806227 P580 "2020-01-13T00:00:00Z" @default.
- Q83806227 P582 "2021-06-30T00:00:00Z" @default.
- Q83806227 P6099 Q42824440 @default.
- Q83806227 P8363 Q78089383 @default.